Literature DB >> 11057778

'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.

I Cervenákov1, M Kopecný, M Jancár, D Chovan, M Mal'a.   

Abstract

From 1995 to 1997 the authors have assessed 31 patients with histologically verified advanced carcinoma of the prostate (CaP) and the ensuing symptom of 'hot flush'. Patients underwent transurethral resection of the prostate (TURP), bilateral orchiectomy (OE) and combined androgen blockade (CAB) by the administration of non-steroid antiadrogens. The authors present the mechanism of the genesis of the 'hot flush' symptom as well as its subjective manifestations, methods of laboratory monitoring as well as their experience with the treatment of this symptom. 50 mg tablets cyproterone acetate administered twice daily or Androcur depot 300 mg i.m. inj. once in 14 days were the main factors in the treatment of 'hot flushes' which reduced subjective difficulties in 80.6% of the patients studied.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11057778     DOI: 10.1023/a:1007164319067

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  11 in total

1.  [Therapy of vasomotor syndrome in the treatment of advanced prostatic cancer: apropos of 37 cases].

Authors:  G Ronzoni; L De Giovanni; P Menchinelli; M Meneschincheri
Journal:  Arch Ital Urol Androl       Date:  1998-02

2.  Physiologic basis for hormonal theapy in carcinoma of the prostate.

Authors:  P C Walsh
Journal:  Urol Clin North Am       Date:  1975-02       Impact factor: 2.241

3.  Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.

Authors:  N Bruchovsky; S L Goldenberg; K Akakura; P S Rennie
Journal:  Cancer       Date:  1993-09-01       Impact factor: 6.860

4.  Transdermal clonidine for ameliorating post-orchiectomy hot flashes.

Authors:  C L Loprinzi; R M Goldberg; J R O'Fallon; S K Quella; A W Miser; L A Mynderse; L D Brown; L K Tschetter; M B Wilwerding; M Dose
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

5.  Androcur 50 in the treatment of prostatic carcinoma. Belgian multicentric study with the participation of 30 urologists.

Authors:  C Peetermans; E Roux
Journal:  Acta Urol Belg       Date:  1994-04

6.  A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.

Authors:  J A Smith
Journal:  J Urol       Date:  1994-07       Impact factor: 7.450

7.  A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.

Authors:  S C Thorpe; S Azmatullah; G J Fellows; J C Gingell; P J O'Boyle
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

Review 8.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 9.  Advances and trends in hormonal therapy for advanced prostate cancer.

Authors:  F M Debruyne; G A Dijkman
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

10.  [Hot flashes after orchiectomy in treatment of prostate cancer-- a serious side effect].

Authors:  N P Buchholz; G Mattarelli
Journal:  Z Gerontol       Date:  1994 Sep-Oct
View more
  2 in total

1.  Adverse events associated with hormonal therapy for prostate cancer.

Authors:  Ravi J Kumar; Al Barqawi; E David Crawford
Journal:  Rev Urol       Date:  2005

Review 2.  Preventing and treating the complications of hormone therapy.

Authors:  Ravi J Kumar; Al Barqawi; E David Crawford
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.